Concepedia
Author
Tina Catalano
Also Known As
21
Publications
335
Citations
8
H-Index
0
Concepts
All Affiliations
×
All Concepts
7
288
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
Stephen M. Ansell, Michael B. Maris, Alexander M. Lesokhin, +23
Clinical Cancer Research
2021
183
CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study
Krish Patel, Jeffrey A. Zonder, Dahlia Sano, +12
Blood
26
Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim
Kalpna Desai, Tina Catalano, Gurinder Rai, +2
Clinical Pharmacology in Drug Development
2016
23
A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 Do Not Eat Signal
Christiane Querfeld, John A. Thompson, Matthew H. Taylor, +8
2017
17
Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study
Krish Patel, Radhakrishnan Ramchandren, Michael B. Maris, +12
2020
15
Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial
2018
13
Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies
James M. Foran, Michael Maris, Jennifer Kimberly Lue, +21
11
Page 1